A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36.

@article{Wilkinson2011AHC,
  title={A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36.},
  author={Kim Wilkinson and Justin D Boyd and Marcie Glicksman and Kathryn J. Moore and Joseph S El Khoury},
  journal={The Journal of biological chemistry},
  year={2011},
  volume={286 40},
  pages={34914-22}
}
A pathological hallmark of Alzheimer disease (AD) is deposition of amyloid β (Aβ) in the brain. Aβ binds to microglia via a receptor complex that includes CD36 leading to production of proinflammatory cytokines and neurotoxic reactive oxygen species and subsequent neurodegeneration. Interruption of Aβ binding to CD36 is a potential therapeutic strategy for AD. To identify pharmacologic inhibitors of Aβ binding to CD36, we developed a 384-well plate assay for binding of fluorescently labeled A… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…